ATP-sensitive potassium channel Inhibitors
2 drugsAbout ATP-sensitive potassium channel
The ATP-sensitive potassium channel (KATP channel) regulates cellular excitability and metabolism. Found in pancreatic beta cells, neurons, and cardiac muscle, these channels link cellular metabolic state to electrical activity. They open or close in response to changes in intracellular ATP levels, regulating insulin secretion, neuronal firing, and vascular tone.
KATP channels are a drug target for metabolic diseases. However, there is currently no genetic evidence directly linking KATP channel mutations to specific diseases, which reduces confidence in target validation.
Two approved drugs target KATP channels: PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, and GLYBURIDE AND METFORMIN HYDROCHLORIDE. Both drugs are small molecules, with applications in metabolic disease.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Diabetes Mellitus Type 2 with only 5 trials.
Top ATP-sensitive potassium channel Drugs
HERITAGE and CHARTWELL RX are the only two companies with approved KATP channel-targeting drugs.
Low competition suggests opportunity, but also indicates potential challenges in market viability.
ATP-sensitive potassium channel Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ATP-sensitive potassium channel, using small molecule modality.
Explore novel modalities like biologics to differentiate from existing small molecule KATP channel drugs.
ATP-sensitive potassium channel Clinical Trials 1,069 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 259 | 202 | 26 | 30 | 89% |
| Phase 2 | 299 | 169 | 80 | 49 | 68% |
| Phase 3 | 241 | 188 | 26 | 25 | 88% |
| Phase 4 | 270 | 196 | 38 | 35 | 84% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ATP-sensitive potassium channel Drug Approval Timeline (2013 - 2013)
The first drug was approved in 2004, and the most recent in 2013, spanning a 10-year approval period.
The lack of recent approvals suggests market saturation or challenges in developing new KATP channel-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 5 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 514 clinical trials targeting ATP-sensitive potassium channel.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities